Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

NCT04945772 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa
Retinitis
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration

Interventions

BIOLOGICAL: Gene Therapy Product-MCO-010
PROCEDURE: Sham Injection

Sponsor

Nanoscope Therapeutics Inc.